ACIP Meeting: June 2024 – CDC Summary
- The Advisory Committee on Immunization Practices (ACIP) recently convened to discuss and update recommendations for several key vaccines, including those for respiratory syncytial virus (RSV), COVID-19, and influenza.The...
- The Centers for Disease Control and prevention (CDC) reviews ACIP recommendations; if adopted, they become official U.S.
- The ACIP reviewed data concerning three RSV vaccines from GSK, Moderna, and Pfizer.
The ACIP has released crucial updates to vaccine recommendations this June. The primary takeaway: adults 75+ and at-risk 60-74 year olds should get an RSV vaccine. Moreover, the updated 2024-2025 COVID-19 vaccine is recommended for everyone 6 months and older, plus routine flu shots are advised for all from 6 months on. Major topics discussed include pneumococcal vaccines and the discontinuation of the Dengue vaccine in the US. These expert decisions impact public health guidance on vaccinations. The CDC’s role in reviewing and implementing these ACIP recommendations is critical. Follow the latest ACIP guidelines to keep your family safe. For more details on these, and future updates, visit News Directory 3. Discover what’s next.
ACIP Updates Vaccine Recommendations for RSV, COVID-19 and Flu
Updated June 08, 2025
The Advisory Committee on Immunization Practices (ACIP) recently convened to discuss and update recommendations for several key vaccines, including those for respiratory syncytial virus (RSV), COVID-19, and influenza.The committee’s discussions, held june 26-28, covered a range of data and considerations for vaccine use across different age groups and risk categories.
The Centers for Disease Control and prevention (CDC) reviews ACIP recommendations; if adopted, they become official U.S. public health guidance, published in the Morbidity and Mortality Weekly Report (MMWR).
RSV Vaccines for Adults
The ACIP reviewed data concerning three RSV vaccines from GSK, Moderna, and Pfizer. Prior to the COVID-19 pandemic, RSV was estimated to cause 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths annually among adults 65 and older in the U.S.
The committee voted unanimously to recommend a single dose of an RSV vaccine for adults aged 75 and older. A separate unanimous motion also recommended a single dose for adults aged 60 to 74 who are at increased risk of severe RSV disease, including those with chronic conditions like lung or heart disease, or those residing in nursing homes. These RSV vaccine recommendations aim to reduce the burden of RSV in older adults.
COVID-19 Vaccine update
The ACIP also addressed the COVID-19 vaccine,voting unanimously to recommend the updated 2024-2025 COVID-19 vaccine for everyone ages 6 months and older,as authorized or approved by the Food and Drug Administration (FDA). The updated COVID-19 vaccine is expected to be available in the fall of 2024.
Influenza Vaccines for 2024-2025
For the upcoming 2024-2025 flu season, the ACIP voted unanimously to recommend routine influenza vaccination for everyone 6 months and older.The updated flu vaccines will be trivalent, protecting against H1N1, H3N2, and a B/Victoria lineage virus.
The committee also recommended that high-dose and adjuvanted inactivated influenza vaccines are acceptable options for influenza vaccination of solid organ transplant recipients aged 18-64 years who are taking immunosuppressive medication regimens.
Pneumococcal Vaccine
The ACIP voted to recommend PCV21 as an option for adults aged 19 years and older who currently have a proposal to receive a dose of PCV.PCV21 covers 81% of the pneumococcal serotypes commonly found in adults.
Other Discussions
The ACIP also discussed the discontinuation of Dengue Tetravalent vaccine (Live, Attenuated) [Dengvaxia®] in the U.S. and revisited the adolescent meningococcal vaccine schedule to optimize protection for the higher-risk ages.
What’s next
The ACIP will continue discussions on the meningococcal vaccine schedule at its October 2024 meeting. Additionally, a new work group on HPV will convene in July 2024 to review current recommendations.